BFM
AXSM icon

Boothbay Fund Management’s Axsome Therapeutics AXSM Stock Holding History

Boothbay Fund Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.58M Buy
+6,436
New +$1.4M 0.02% 848
2025
Q3 		– Sell
-5,000
Closed -$522K – 1872
2025
Q2 		$522K Buy
+5,000
New +$529K 0.01% 890
2022
Q1 		– Sell
-13,447
Closed -$417K – 2264
2021
Q4 		$508K Buy
+13,447
New +$495K 0.01% 1005

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Boothbay Fund Management's AXSM Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 6,436 shares worth $1.58M. The stake represents 0.02% of the portfolio and ranks #848 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in AXSM as recently as Q2 2025.

Boothbay Fund Management first reported a position in AXSM in Q4 2021 and has held it in 3 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Boothbay Fund Management held 6,436 shares of Axsome Therapeutics worth $1.58M as of Q2 2026.
  • Axsome Therapeutics was a new Boothbay Fund Management position in Q2 2026.
  • Axsome Therapeutics made up 0.02% of Boothbay Fund Management's portfolio in Q2 2026, its #848 holding.
  • Boothbay Fund Management first reported a position in Axsome Therapeutics in Q4 2021 and has held it in 3 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.